Okomera is a biotech startup developing cutting-edge solutions for oncology drug discovery and will present their technology in SLAS 2025,in San Diego January 25 to 29, 2025. Okomera will showcase its ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

A cutting-edge scientific simulation platform for studying drug responses in organoids using advanced machine learning and interactive data visualization technologies. This project provides a ...

"Our aim is to provide pharmaceutical companies and clinical researchers with scalable, high-throughput tools for oncology drug discovery." Okomera's platform integrates automated organoid ...

This project provides a web-based interface for simulating and analyzing how organoids respond to various drugs. It combines biological simulation with machine learning predictions to help researchers ...

This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to address ...

This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...